What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals

Loading...
Loading...

Alnylam Pharmaceuticals ALNY has observed the following analyst ratings within the last quarter:

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 2 7 0 0
Last 30D 1 0 0 0 0
1M Ago 0 2 2 0 0
2M Ago 2 0 2 0 0
3M Ago 0 0 3 0 0

According to 12 analyst offering 12-month price targets in the last 3 months, Alnylam Pharmaceuticals has an average price target of $213.75 with a high of $256.00 and a low of $159.00.

Below is a summary of how these 12 analysts rated Alnylam Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average has increased by 12.29% from the previous average price target of $190.36.

Analyst Ratings: What Are They?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...